S. Moulec

发表

Whole-brain radiation therapy in breast cancer patients with brain metastases

Cyrus Chargari, J. Pierga, D. Ricard, 2010, Nature Reviews Clinical Oncology.

Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.

M. Zauderer, R. Cameron, D. Planchard, 2018 .

Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE.

O. Molinier, G. Zalcman, P. Dumont, 2016 .

Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy

J. Calvet, F. Goldwasser, T. Maisonobe, 2016, Journal of Neuro-Oncology.

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

C. Rudin, R. Govindan, D. Carbone, 2018, Pneumologie.

Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.

S. Oudard, G. Gravis, P. Beuzeboc, 2013 .

1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)

D. Planchard, J. Soria, S. Koscielny, 2017 .

Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).

S. Oudard, G. Gravis, P. Beuzeboc, 2014 .

Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.

D. Spaeth, S. Oudard, S. Chowdhury, 2019, Journal of Clinical Oncology.

880PBiomarkers before and after nephrectomy of locally advanced or metastatic renal cell carcinoma (RCC) treated with everolimus: Neorad phase 2 trial (PREDICT consortium)

C. Tournigand, L. Salomon, C. Swanton, 2017 .

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

First case of posterior reversible encephalopathy syndrome associated with vinflunine

D. Ricard, M. Lahutte, C. Helissey, 2012, Investigational New Drugs.

Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.

D. Planchard, J. Adam, J. Soria, 2020, JCO precision oncology.

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

N. Reinmuth, M. Ahn, S. Peters, 2018, Annals of Oncology.

Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

F. Saad, K. Miller, C. Sternberg, 2015 .

MA 10.11 Hyperprogressive Disease (HPD) Is Frequent in Non-Small Cell Lung Cancer (NSCLC) Patients (Pts) Treated with Anti PD1/PD-L1 Agents (IO)

D. Planchard, J. Soria, G. Tortora, 2017 .

MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

C. Lefebvre, D. Ruysscher, D. Planchard, 2018, Journal of Thoracic Oncology.

7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial

S. Culine, S. Oudard, N. Houédé, 2011 .

Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous NSCLC (ns-NSCLC) patients with asymptomatic untreated brain metastases (BM) (BRAIN).

J. Soria, J. Mazières, D. Moro-Sibilot, 2013 .

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

D. Planchard, F. André, J. Soria, 2011, British Journal of Cancer.

OA11.01 Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study

O. Molinier, G. Zalcman, P. Dumont, 2017 .

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

C. Lindsay, P. Vielh, Y. Loriot, 2016, BMC Cancer.

112PPathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)

D. Planchard, J. Adam, J. Soria, 2017 .

Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study

R. Govindan, D. Morgensztern, A. Dowlati, 2019, Pneumologie.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

C. Lindsay, P. Vielh, Y. Loriot, 2016, BMC Cancer.